After it announced the lengths that will go to in order to have the proper conditions to distribute its potential COVID-19 vaccine, Pfizer made public its Q3 earnings.
The New York-based company reported earnings per share of 0.72 cents on revenue of $12.13 billion. While the EPS came higher than the 0.69 cents expected, the revenue fell short of the $12.31 billion mark.
Along with the Q3 figures came other news. According to Pfizer’s statement, the company’s not ready to go public with the data it collected during the late-stage trials of its potential COVID-19 vaccine that it’s developing alongside Germany’s BioNTech. Pfizer said that the independent monitor hadn’t conducted an in-depth analysis to show whether the drug was efficient.
Since the beginning of the year, the company’s stock price fell 3%, while USA500 gained 4.45%.
Read here more about Pfizer!
Sources: investing.com, reuters.com
